MedTrace Logo

Alcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or Ketamine

NCT03788889 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2019-09-19

No results posted yet for this study

Summary

The goal of this study will aim to determine if adding phenobarbital or ketamine to a symptom-triggered benzodiazepine regimen decreases the rate of intensive care unit admissions during the treatment of alcohol withdrawal syndrome when compared to symptom-triggered benzodiazepine therapy alone.

Conditions

  • Alcohol Withdrawal Syndrome

Interventions

DRUG

Ketamine

Ketamine infusion

DRUG

Phenobarbital

Phenobarbital intravenous injection

DRUG

Lorazepam

Standard of Care

DRUG

Placebo A

Placebo injection

DRUG

Placebo B

Placebo infusion

Sponsors & Collaborators

  • Santa Barbara Cottage Hospital

    lead OTHER

Principal Investigators

  • Noah Stites-Hallet, MD · Santa Barbara Cottage Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-12
Primary Completion
2019-04-12
Completion
2019-04-12
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03788889 on ClinicalTrials.gov